But in the meantime, Gilead and HHS are also partners in a free drug distribution program after Gilead`s extensive fundraising contract last year. And as the COVID 19 pandemic unfolds, the company has stated that it is committed to helping with this response. Gileads Remdesivir is one of the most promising active candidates against COVID-19, although recent early data on the drug have raised questions about its efficacy. Gilead referred the federal government to the Federal Claims Court on Friday, saying the Centers for Disease Control and Prevention (CDC) had violated four equipment transfer agreements and a clinical trial agreement. “Under President Trump`s leadership, HHS worked with Gilead to secure preventative drugs for people who would otherwise not be able to access this important treatment or afford this important treatment. The majority of Americans who are at risk and who could protect themselves with PrEP still do not receive this drug. This agreement will help fill that gap and fulfill President Trump`s promise to end the HIV epidemic in America. – by Caitlyn Stulpin The agreements between the company and the agency “governed the conditions of more than 15 years of cooperation” between the parties to anti-HIV drugs, and Gilead says the government violated the terms of the agreements by seeking its own patents. The agreement between HHS and Gilead will last until 31 December 2025 and possibly until 31 December 2030 and will provide truvada (emtricitabine/fumarate of tenofovir disoproxil), FTC/TDF) to uninsured people who are at risk of HIV, HHS said. In particular, Gilead says the federal government applied for patent protection for the anti-HIV drug Truvada, without notifying the company, as was required.
As part of the agreements, Gilead says, the company provided “significant” amounts of drugs to federal researchers “free of charge” for studies. The government, on the other hand, was responsible for notifying the company if it made any discoveries. The clinical trial agreement provided that U.S. officials would not attempt to patent the plant, according to the complaint. Gilead has patient assistance programs in the United States to help people who need funding to access Truvada for PrEP. For those eligible for commercial insurance, Gilead offers copay coupon support, which allows patients to pay as little as $0 per bottle for Truvada for PrEP. People without insurance can use truvada for PrEP for free through our long-standing medical assistance program or, in the near future, through the new CDC-Gilead partnership. Those interested in learning more about the support programs available to them are encouraged to visit Gilead Advancing Access®`s website at www.gileadadvancingaccess.com.
For more information about Gilead Sciences, visit the company`s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Gilead has so far disputed any link between the patents and its deal to make HIV preventative pills available free of charge. The San Francisco-based company announced that it would donate 2.4 million bottles of Truvada per year to PrEP.
